StockNews.com Upgrades Syndax Pharmaceuticals (NASDAQ:SNDX) to “Hold”

Syndax Pharmaceuticals (NASDAQ:SNDX) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Friday.

Several other equities research analysts have also commented on the company. Citigroup upped their price objective on Syndax Pharmaceuticals from $30.00 to $34.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Bank of America lifted their price objective on shares of Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a “buy” rating in a report on Thursday, August 15th. Barclays upped their price objective on shares of Syndax Pharmaceuticals from $32.00 to $33.00 and gave the stock an “overweight” rating in a research report on Thursday, August 15th. HC Wainwright raised their target price on Syndax Pharmaceuticals from $47.00 to $49.00 and gave the company a “buy” rating in a research report on Tuesday, November 12th. Finally, UBS Group started coverage on Syndax Pharmaceuticals in a report on Thursday, October 24th. They issued a “buy” rating and a $37.00 price target for the company. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $36.00.

Syndax Pharmaceuticals Price Performance

NASDAQ SNDX opened at $15.83 on Friday. Syndax Pharmaceuticals has a 1 year low of $14.50 and a 1 year high of $25.34. The company has a market capitalization of $1.35 billion, a PE ratio of -4.36 and a beta of 0.92. The company has a fifty day moving average of $18.87 and a 200 day moving average of $20.21.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.13) by $0.15. The company had revenue of $12.50 million during the quarter, compared to analyst estimates of $9.16 million. During the same period last year, the firm earned ($0.73) EPS. Research analysts expect that Syndax Pharmaceuticals will post -3.61 earnings per share for the current year.

Institutional Trading of Syndax Pharmaceuticals

Large investors have recently made changes to their positions in the company. Swiss National Bank lifted its holdings in Syndax Pharmaceuticals by 5.8% in the 1st quarter. Swiss National Bank now owns 150,600 shares of the company’s stock valued at $3,584,000 after purchasing an additional 8,200 shares in the last quarter. Sei Investments Co. boosted its position in Syndax Pharmaceuticals by 2.5% during the first quarter. Sei Investments Co. now owns 40,463 shares of the company’s stock worth $963,000 after acquiring an additional 991 shares during the last quarter. ProShare Advisors LLC grew its stake in Syndax Pharmaceuticals by 29.6% during the 1st quarter. ProShare Advisors LLC now owns 20,112 shares of the company’s stock valued at $479,000 after acquiring an additional 4,599 shares in the last quarter. Vanguard Group Inc. grew its stake in Syndax Pharmaceuticals by 13.6% during the 1st quarter. Vanguard Group Inc. now owns 4,926,984 shares of the company’s stock valued at $117,262,000 after acquiring an additional 591,631 shares in the last quarter. Finally, Ameritas Investment Partners Inc. lifted its stake in Syndax Pharmaceuticals by 20.0% in the 1st quarter. Ameritas Investment Partners Inc. now owns 7,858 shares of the company’s stock worth $187,000 after purchasing an additional 1,312 shares in the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).